explore -WSS

explore

author：knowledge 2025-09-27 09:38:19 - browse：86498

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Getting Alzheimer's drug Leqembi to patients can be a challenge

focus

WSS

Dogs on Prozac: What pet anti

Close Medicare's dangerous gaps in addiction treatment coverage

Ukraine and a new approach to mental health in war

Element Biosciences CEO lays out genome sequencing strategy

Cholera vaccine supply gets boost as demand surges globally

Bird flu in milk supply is likely coming from asymptomatic cows

hotspot

explore

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Medical student insurance fails on mental health care coverage

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Diversity in clinical trials starts with building trust, experts say

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Cell therapy fails to slow type 1 diabetes, but safety is established

DIEP, the 'gold standard' of breast reconstruction, is under threat

UnitedHealth financials solid despite Change Healthcare cyberattack

Trump demands the U.S. pay no more for drugs than other countries … again

Melinda French Gates resigns from Gates Foundation

Wikipedia

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Readout LOUD podcast: possible new ALS drug, artificial wombs

Senate HELP committee spars over health care workforce policies

Intarcia’s device

Orangutan used medicinal plant to treat wound, first time ever seen

Senate HELP committee spars over health care workforce policies

focus

focus

leisure time

entertainment